Proteomics

Dataset Information

0

Endogenous anti-tumorigenic nitro-fatty acids potently suppress the ubiquitin-proteasome system


ABSTRACT: Nitro-fatty acids (NFAs) are endogenously formed lipid mediators that cause a broad spectrum of anti-inflammatory effects by covalent modification of key proteins within inflammatory signaling pathways. Their potential as therapeutics has been demonstrated in numerous animal models of disease. Herein, we evaluated the anti-tumorigenic effects of NFAs in the colon carcinoma cell line Caco-2 and other solid and leukemic tumor cell lines. NFAs inhibited the ubiquitin–proteasome system (UPS), leading to polyubiquitination and inhibition of the proteasome activities. Suppression of the UPS induced the pro-apoptotic transcription factor CHOP by activation of the unfolded protein response (UPR), resulting in tumor cell death. NFA-mediated effects on UPS and UPR were rather strong, highly specific, largely irreversible, and represent a mechanistically new mode of action for pharmacological suppression of the UPS. Taking into account their favorable safety profile in clinical phase I trials in combination with their well-recognized anti-tumorigenic efficacy covering solid tumors, we conclude that NFAs are innovative proteasome inhibitor drug candidates that may have a large potential to overcome the limitations of the classical proteasome inhibitors.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

DISEASE(S): Colon Cancer

SUBMITTER: Shady Amr  

LAB HEAD: Dr. Christian Münch

PROVIDER: PXD023372 | Pride | 2024-03-26

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
20190729_GT_SA_Col_F.msf Msf
20190729_GT_SA_Col_F1.raw Raw
20190729_GT_SA_Col_F2.raw Raw
20190729_GT_SA_Col_F3.raw Raw
20190729_GT_SA_Col_F4.raw Raw
Items per page:
1 - 5 of 28

Similar Datasets

2021-09-09 | PXD018090 | Pride
2022-09-03 | PXD022560 | Pride
2024-03-19 | PXD050731 | Pride
2024-03-26 | PXD041458 | Pride
2024-03-26 | PXD035951 | Pride
2022-09-03 | PXD022530 | Pride
2021-12-18 | PXD022521 | Pride
2021-09-10 | PXD024044 | Pride
2021-12-20 | PXD024066 | Pride
2020-07-20 | PXD017710 | Pride